News

The launch follows a decision from the US District Court for the District of New Jersey that US Patent No. 7,524,834 is invalid, and AstraZeneca’s request for a

Erbitux is a highly active IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Merck has already positioned Japan as its regional Research and Development hub

The approval was based on data from a multicenter, randomized, double-blind, placebo-controlled Phase III SELECT trial. A total of 392 patients were included in the trial, in which

The company has submitted a new drug application (NDA) under the FDA’s fast track program and is based on results from the PARADIGM-HF trial, which is claimed to

Kerasal Complete Care brings together two highly effective treatments to restore healthy nail appearance and treat toe and foot skin fungus (athlete’s foot) in a convenient dual-pack. Moberg

The drug is indicated to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release

Simultaneously, the company has requested the FDA for fast track designation for Actimmune. The company also intends to commence a Phase III trial in the second quarter of

As part of the deal, Lonza will manufacture material for the Phase III trial of Cx601 in the US at Lonza’s cell therapy production facility in Walkersville, US.

In September 2014, the company reported positive results from a Phase II trial of MOB-015. The new patent includes composition of matter claims directed to a new topical